Cash/Burn From SEC Filing For Period: 

Q1 '20

KPTI

Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases.

Cash

$352.1M

Burn Rate

-$52.9M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

XPOVIO (Selinexor)

Multiple myeloma (Penta-Refractory) | STORM

Quarterly Sales (Approved)

November 4, 2020 (Est)

Selinexor (Xpovio)

Diffuse Large B -Cell Lymphoma DLBCL | SADAL

Quarterly Sales

November 4, 2020 (Est)

Selinexor

Liposarcoma | SEAL

Phase 2/3 (Top-line Data)

H2 2020

Selinexor

Diffuse Large B- Cell Lymphoma (combination with rituximnab-gemcitabine-dex-platinum) | XPORT_DLBCL-030)

Phase 3

TBD

Selinexor

Endometrial Cancer | SIENDO

Phase 2/3

TBD

Selinexor

Multiple myeloma (Relapsed/Refractory) | BOSTON

PDUFA

March 19, 2021

Selinexor, XPOVIO (Moderate or Severe COVID-19)

COVID-19 Therapy

Phase 2 (Data)

TBD

Eltanexor

Myelodysplastic Syndrome (MDS)

Phase 2

TBD

Selinexor

Multiple myeloma (Relapsed/Refractory and Front line) | STOMP

Phase 1b/2

TBD

Eltanexor

Colorectal Cancer (CRC) and Prostate Cancer (PrC)

Phase 1/2

TBD

KPT-9274

Solid Tumors & Lymphoma

Phase 1

TBD

KPT-9274

Cancer

Phase 1

TBD

Selinexor

Diffuse Large B-cell Lymphoma (Combination with Chemo and non-chemo) | XPORT-DLBCL-025

Phase 1

TBD

Selinexor

CRC (combination with pembrolizumab) and NSCLC (combination with docetaxel) | XPORT-STP-027

Phase 1

TBD

Recent Posts

See What The Community Is Saying - Click To See Full Post

#KPTI - #PDUFA Date for #XPOVI...

Supplemental New Drug Application for XPOVIO as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy Accepted by FDA and Assigned a Target PDUFA Date of March 19, 20...

KPTI's Upcoming ASCO Presentat...

We invest in KPTI because they have an enterprise value below $2 billion, and an approved oral blood cancer drug, XPOVIO (Selinexor), with a new mechanism of action and blockbuster potential. XPOVIO i...

#KPTI - Interim Analysis & Nex...

#KPTI announced that "interim analysis of the randomized Phase 2 study of low dose selinexor in patients with severe COVID-19 indicated that while the agent is unlikely to demonstrate a statistically ...

KPTI dilution event not a surp...

After reporting positive top-line Phase 3 results today, KTPI announced a follow-on offering. I provide more details about why this is not surprising as a comment to my Amp educational video to follow...

KPTI's Q2 XPOVIO Net Sales...

KPTI announced their Q2 2020 XPOVIO net product sales of $18.6 Million. See AmpCard for more details. #KPTI, #XPOVIO, #SELINEXOR, #Multiple_myeloma, #STORM...

Educational video - Near-term ...

Check out my recent video in our educational forum, which discusses the unfortunate reality of small and mid-cap biopharma investing: near-term dilution. Case studies are provided for CARA and TGTX, ...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon